Opus Genetics stock
IRDNASDAQOpus Genetics, Inc., HealthcareISIN US67577R1023
43Score 43 out of 100, Weak
Price and trend
66 / 100
Price history
+111% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.6% below it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 33% below its 52-week high. Largest decline in 2 years: 51% (January 2025 to April 2025).
Chart figures for advanced users
- SMA 50$4.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$4.26
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.74
- The lowest closing price of the last twelve months.
- Resistance$6.07
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Opus Genetics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $337.77M, is number 278 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $14.2M (up 29.1% year on year) and a loss of $49.59M.
- For fiscal 2026, analysts expect on average revenue of $12.21M (down 14%) and adjusted earnings per share of −$1.03.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 503 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $88.97M, financial debt $34.53M.
Weaknesses
- Loss-makingLoss of $136.65M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 81% a year over the last 12 months.Stability 44
- Negative free cash flowFree cash flow −$48.74M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 42 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 7.5). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 45.9% on the twelve months before. Revenue turned from negative at the start of the period to positive ($14.2M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −272%, net −349%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Mar 2027in 117 days
- Last reported
- 10 Nov 2026EPS reported −$0.46 (expected −$0.15)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.03+0.7%
- Revenue
- $12.21M+5.9%
- Earnings per share
- −$0.700.0%
- Revenue
- $11.94M+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $10.69M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Magrath GeorgeSale
3 Nov 2026, Chief Executive Officer
- Shares
- 28,258
- Price
- $3.90
- Value
- $110,184
- Schachle Joseph KSale
23 Oct 2026, Chief Operating Officer
- Shares
- 4,767
- Price
- $3.57
- Value
- $16,994
- Yerxa Benjamin RSale
23 Oct 2026, President
- Shares
- 33,189
- Price
- $3.54
- Value
- $117,365
Show 9 more
- Gagnon Robert E.Sale
23 Oct 2026, Chief Financial Officer
- Shares
- 14,000
- Price
- $3.55
- Value
- $49,650
- Magrath GeorgeSale
23 Oct 2026, Chief Executive Officer
- Shares
- 9,591
- Price
- $3.59
- Value
- $34,384
- Foundation Fighting Blindness Retinal Degeneration FundSale
30 Sept 2026, Board
- Shares
- 556,000
- Price
- $4.96
- Value
- $2.76M
- Gagnon Robert E.Sale
3 Sept 2026, Chief Financial Officer
- Shares
- 28,000
- Price
- $4.54
- Value
- $127,212
- Yerxa Benjamin RSale
23 Jul 2026, President
- Shares
- 7,429
- Price
- $2.97
- Value
- $22,064
- Schachle Joseph KSale
23 Jul 2026, Chief Operating Officer
- Shares
- 4,644
- Price
- $2.94
- Value
- $13,653
- Magrath GeorgeSale
23 Jul 2026, Chief Executive Officer
- Shares
- 9,475
- Price
- $2.95
- Value
- $27,926
- Gagnon Robert E.Sale
23 Jul 2026, Chief Financial Officer
- Shares
- 7,783
- Price
- $2.95
- Value
- $22,942
- Foundation Fighting Blindness Retinal Degeneration FundSale
18 May 2026, Board
- Shares
- 1,700,000
- Price
- $4.35
- Value
- $7.39M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Opus Genetics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Editas MedicineEDIT $365.52M28
- PepGenPEPG $363.83M43
- Orchestra BioMed HoldingsOBIO $361.23M49
- Eikon TherapeuticsEIKN $361.1M35
- Century TherapeuticsIPSC $358.05M37
- AgomAb TherapeuticsAGMB $344.24M30
- Faeth TherapeuticsFTH $344.15M35
- Atea PharmaceuticalsAVIR $338.46M35
ETFs that hold Opus Genetics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Feb 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.